3D Global Biotech (6808.TWO) has a profit margin of 30.59%, above the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
3D Global Biotech (6808.TWO) currently reports a profit margin of 30.59% as of June 2026. That compares with -131.29% in the prior-year period — up 123.3% year over year. That is above the Healthcare sector average of 17.63%. Use the charts on this page to explore 3D Global Biotech's profit margin history and peer comparisons.
3D Global Biotech's profit margin increased from -131.29% to 30.59% — a 123.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
3D Global Biotech's profit margin of 30.59% is higher than the Healthcare sector average of 17.63%. That is roughly 73.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but 3D Global Biotech's current 30.59% should be judged against Healthcare norms (sector average: 17.63%) and against 6808.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of 30.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for 3D Global Biotech, and consider following 6808.TWO for alerts when major investors trade the stock.